Sonia Mansourian Hosseini; Soodabeh Aliashrafi; Mehrangiz Ebrahimi-Mameghani
Volume 20, Issue 10 , 2018, Pages 1-12
Abstract
Background: Due to the fact that there is evidence indicating the role of Vitamin D in non-alcoholic fatty liver disease (NAFLD) as well as insulin resistance (IR) and adipokines production, studies examining Vitamin D on the metabolic factors involving NAFLD is required. Objectives: Therefore, we aimed ...
Read More
Background: Due to the fact that there is evidence indicating the role of Vitamin D in non-alcoholic fatty liver disease (NAFLD) as well as insulin resistance (IR) and adipokines production, studies examining Vitamin D on the metabolic factors involving NAFLD is required. Objectives: Therefore, we aimed to investigate the effect of single intramuscular injection of cholecalciferol on serum levels of Vitamin D, biochemical factors, and liver function status of women with NAFLD. Methods: This randomized controlled clinical trial was conducted on 82 NAFLD patients with Vitamin D deficiency (< 30 ng/mL), who were selected through convenience sampling from October 2015 to March 2016 in Tabriz, Iran, and were randomly assigned into an intervention (a single intramuscular injection of 600,000 IU of cholecalciferol) or control group. Before and after the study, serum glucose, insulin, 25-hydroxy Vitamin D, adiponectin, liver enzymes, calcium, phosphors and parathyroid hormone (PTH), as well as homeostasis model assessment (HOMA-IR), body composition, dietary intake, and physical activity level were assessed. Results: After one month intervention, serum 25-hydroxyvitamin D significantly increased in the intervention group vs. the con- trol (24.9 ± 17.4 vs. 9.1 ± 5.6, P = 0.003). Total body fat (TF) decreased in the intervention group (P = 0.001) while visceral fat (VF) was significantly different between the groups (P < 0.001). Adiponectin, calcium, phosphors, and PTH levels increased, while liver enzymes, insulin, and HOMA-IR decreased in both groups (P < 0.05). There were significant differences in mean changes of serum 25(OH) D, PTH, ALT, AST, ALP, and FBS between the groups after adjusting for baseline, TF and VF. Vitamin D injection did improve NAFLD severity (P = 0.01). Conclusions: Cholecalciferol injection improved Vitamin D status and hepatic steatosis.
Farshad Amirkhizi; Soudabeh Hamedi-Shahraki; Sonya Hosseinpour-Arjmand; Elnaz Vaghef-Mehrabany; Mehrangiz Ebrahimi-Mameghani
Volume 20, Issue 9 , 2018, Pages 1-11
Abstract
Background: Several mechanisms have been suggested to explain the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression, one of which is increased oxidative stress. Objectives: This study aimed to evaluate the effect of alpha-lipoic acid (ALA) supplementation on anthropometric ...
Read More
Background: Several mechanisms have been suggested to explain the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression, one of which is increased oxidative stress. Objectives: This study aimed to evaluate the effect of alpha-lipoic acid (ALA) supplementation on anthropometric indices, dietary intake and oxidative stress-related parameters in obese patients with NAFLD. Methods: In this double-blind, placebo-controlled trial, 50 NAFLD patients were assigned to two groups of receiving 1200 mg ALA (two 600 mg capsules of ALA) and placebo (two 600 mg capsules of placebo) for 12 weeks. Serum liver enzymes, malondialdehyde (MDA) level, total antioxidant status (TAS), and the activities of copper-zinc superoxide dismutase (Cu/Zn-SOD) and glutathione per- oxidase (GSH-Px) were assessed at baseline and after 12 weeks of intervention. Results: Serum concentrations of liver enzymes decreased significantly in the ALA group (P < 0.05 for all), while a noticeable decline was observed for alanine aminotransferase (ALT) in the placebo group (32.5 ± 18.9 vs. 25.9 ± 11.2; P = 0.034). Nonetheless, there were no significant differences between the study groups concerning serum liver enzymes concentrations post-intervention. AlthoughALA supplementation significantly reduced the serum concentration of MDA (2.52 ± 0.35 vs. 2.77 ± 0.49; P < 0.040) and increased serum TAS (1.73 ± 0.55 vs. 1.52 ± 0.34; P < 0.048), other oxidative stress-related parameters such as Cu/Zn-SOD and GSH-Px activities were not affected. Conclusions: These findings suggest that daily supplementation of 1200 mg alpha-lipoic acid (ALA) for 12 weeks improves oxidative stress markers in patients with nonalcoholic fatty liver disease (NAFLD) and it could be considered as adjunctive therapy for the prevention of NAFLD progression.
Sonya Hosseinpour-Arjmand; Soudabeh Hamedi-Shahraki; Mehrangiz Ebrahimi-Mameghani; Farshad Amirkhizi
Volume 20, Issue 3 , 2018, Pages 1-11
Abstract
Background: Insulin resistance has a pivotal role in the occurrence of impaired glucose tolerance and dyslipidemia in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). There is evidence of possible beneficial effects of Alpha-Lipoic Acid (ALA) on insulin resistance and metabolic disorders. Objectives: ...
Read More
Background: Insulin resistance has a pivotal role in the occurrence of impaired glucose tolerance and dyslipidemia in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). There is evidence of possible beneficial effects of Alpha-Lipoic Acid (ALA) on insulin resistance and metabolic disorders. Objectives: This study aimed at examining the effects of ALA supplementation on liver enzymes, insulin sensitivity, glucose markers, and lipid profile in obese patients with NAFLD.Methods: In this double-blind placebo-controlled randomized clinical trial, 50 obese patients with NAFLD were randomly allocated to “ALA group” (received 1200 mg ALA as two capsules per day) or “Placebo group” (received placebo containing cornstarch as two capsules per day) for 12 weeks. Anthropometric measures, dietary intakes, liver enzymes as well as glucose markers and lipid profile were assessed at baseline and after 12 weeks of intervention.Results: Forty-five patients completed the study (ALA group = 23; placebo group = 22). Liver enzymes were not significantly altered by the intervention group. Alpha Lipoic Acid supplementation led to a significant attenuation in serum levels of insulin (13.4 ± 5.4 vs. 18.1 ± 8.6; P = 0.019) and triglyceride (146.9 ± 60.6 vs. 186.3 ± 54.2; P = 0.037) in comparison with the placebo group, yet did not affect other lipid profile parameters, Fasting Serum Glucose (FSG) and β-cell function index (HOMA-B) in patients with NAFLD. furthermore, quantitative insulin sensitivity check index (QUICKI) increased significantly in the ALA group compared to the placebo (0.329 ± 0.025 versus 0.317 ± 0.020; P = 0.033).Conclusions: Patients with NAFLD may benefit from ALA supplementation, at least partially through augmented insulin sensitivity and improvement of lipid profile
Somayeh Mohammadi; Seyed Rafie Arefhosseini; Mohammad Asghari Jafarabadi; Zarin Sharifnia; Mehrangiz Ebrahimi-Mameghani
Volume 19, Issue 1 , January 2017, , Pages 1-8
Abstract
Background: Obesity is the main cause of insulin resistance and type 2 diabetes mellitus (T2DM). Diet therapy is the cornerstone in the management of obesity and T2DM.Objectives: We evaluated the effects of calorie-restricted diet therapy on the circulating level of the serum lipid profile, glucose, ...
Read More
Background: Obesity is the main cause of insulin resistance and type 2 diabetes mellitus (T2DM). Diet therapy is the cornerstone in the management of obesity and T2DM.Objectives: We evaluated the effects of calorie-restricted diet therapy on the circulating level of the serum lipid profile, glucose, insulin, and adiponectin in obese women with T2DM.Materials and Methods: This randomized clinical controlled trial was performed for 10 weeks on 30 eligible obese T2DM women distributed to control (n = 15) and diet therapy (n = 15) groups. Demographic, nutritional, anthropometric, and laboratory data were obtained before and after the study. Data were analyzed by SPSS vs.15 and Nutritionist IV.Results: In addition to anthropometric measurements, diet therapy independently improved fasting blood sugar (P = 0.024, -69.37 to -5.57 mg/dL), 2-h postprandial blood sugar (P = 0.007, -123.34 to -22.3 mg/dL), serum total cholesterol (P = 0.005, -46.48 to -9.72 mg/dL), serum alanine transaminase (P = 0.001, -8.91 to -3.18 U/L), and increased circulating adiponectin (P = 0.038, 0.01 to 0.47 µg/mL).Conclusions: Improvement of biomarkers of insulin sensitivity, including adiponectin and lipid metabolism, is an important therapeutic effect of medical nutrition therapy in obese patients with T2DM.
Somayeh Mohammadi; Mehrangiz Ebrahimi-Mameghani; Seyed Rafie Arefhosseini; Parviz Fallah; Mohammad Asghari Jafarabadi; Sepideh Zununi; Masoud Soleimani; Mehdi Banitalebi Dehkordi; Hossein Ghanbarian
Volume 19, Issue 1 , January 2017, , Pages 1-10
Abstract
Background: MicroRNAs have recently been introduced as epigenetic regulators of glucose and lipid metabolic pathways, which are impaired in obesity and diabetes.Objectives: We evaluated the effects of calorie-restricted diet therapy on the circulating levels of miR-33b and miR-29a in relationship to ...
Read More
Background: MicroRNAs have recently been introduced as epigenetic regulators of glucose and lipid metabolic pathways, which are impaired in obesity and diabetes.Objectives: We evaluated the effects of calorie-restricted diet therapy on the circulating levels of miR-33b and miR-29a in relationship to glucose and lipid metabolic parameters in obese patients with type 2 diabetes mellitus (T2DM).Methods: This randomized clinical controlled trial was performed on 30 eligible obese women with T2DM, randomly divided into two groups (control group, n = 15; diet therapy group, n = 15) for 10 weeks. Ten healthy women with normal weight were enrolled at the baseline of the study as controls. Demographic information, dietary intake, and anthropometric and biochemical indices were obtained before and after the study. Circulating miR-33b and miR-29a were assessed for all subjects using quantitative RT-PCR, and the fold change of each circulating miRNA was compared between groups.Results: The circulating levels of miR-29a and miR-33b in the diabetic women were higher (0.40-fold) and lower (1.43-fold), respectively, than normal levels. Diet therapy significantly increased the circulating level of miR-33b (P = 0.023, 0.97-fold upregulation) to normal levels. This increase was independently correlated with caloric restriction (95%CI: -0.004 to -0.0001, P = 0.022) and 2hPPBS (95%CI: -0.009 to -0.001, P = 0.035). No remarkable change was observed in circulating levels of miR-29a.Conclusions: Our findings introduced a novel therapeutic effect of diet therapy on circulating miRNAs in obese patients with T2DM. MiR-33b is an important therapeutic target in the treatment and prevention of T2DM and its complications.
